In fact, the inhibition of glutamine-fructose-6-phosphate transaminase 2 (GFPT2) more potently suppresses tumor growth in cell culture, xenografts and genetically engineered mouse models of NSCLC mutated in KRAS/LKB1 (114). The gene discussed is KRAS; the disease is neoplasm.